IDEAYA Biosciences, Inc. financials

IDYA CIK 0001676725

Source: EDGAR filings · Built 2026-06-03T02:26:40Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -73.47M -251.44M -117.59M -90.62M -58.42M 54.97M
EBITDA -156.61M -324.59M -131.95M -60.40M -48.54M -33.96M
Working Capital 607.91M 643.64M 505.53M 338.74M 205.84M 249.97M
Net Debt -84.91M -65.21M -154.15M -65.15M -86.86M -65.31M
Operating Margin -72.84% -4671.07% -574.85% -122.72% -179.91% -180.90%
Net Margin -51.99% -3921.10% -483.05% -115.17% -178.10% -176.55%
Return on Equity (ROE) -11.11% -25.91% -18.19% -16.78% -16.50% -17.40%
Return on Assets (ROA) -10.25% -24.42% -17.40% -15.12% -13.05% -11.57%
Current Ratio 11.34× 14.97× 19.65× 11.68× 5.56× 7.47×
Debt-to-Equity 0.03× 0.02× 0.00× 0.01× 0.02× 0.03×
Cash Conversion Ratio 0.63× 0.90× 1.02× 1.49× 1.12× -1.61×
Accruals Ratio -0.04× -0.02× 0.00× 0.07× 0.02× -0.30×
SBC % of Revenue 21.09% 496.37% 79.06% 22.83% 29.48% 18.47%
CapEx Coverage -30.02× -64.19× -48.66× -25.32× -21.10× 112.50×
Free Cash Flow Per Share $-0.83 $-3.08 $-2.04 $-2.19 $-1.66 $2.22

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/FCF 6.30×
FCF Yield 15.88%
P/S 13.88× 317.59× 98.96× 17.19× 32.60× 21.16×
P/B 2.97× 2.10× 3.73× 2.51× 3.02× 2.09×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 218.71M 7.00M 23.39M 50.93M 27.94M 19.54M
Research and Development Expense 314.70M 294.67M 129.51M 89.54M 58.16M 39.70M
Operating Expenses 378.02M 333.98M 157.81M 113.43M 78.21M 54.88M
Operating Income (Loss) -159.31M -326.98M -134.43M -62.50M -50.27M -35.34M
Income Tax Expense (Benefit) 0 0 0 0 0 0
Net Income (Loss) Attributable to Parent -113.70M -274.48M -112.96M -58.66M -49.76M -34.49M
Earnings Per Share, Basic $-1.28 $-3.36 $-1.96 $-1.42 $-1.41 $-1.40
Weighted Average Number of Shares Outstanding, Basic 88.49M 81.68M 57.52M 41.44M 35.25M 24.72M
Earnings Per Share, Diluted $-1.28 $-3.36 $-1.96 $-1.42 $-1.41 $-1.40
Weighted Average Number of Shares Outstanding, Diluted 88.49M 81.68M 57.52M 41.44M 35.25M 24.72M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 112.83M 84.38M 157.02M 68.63M 92.05M 72.04M
Assets, Current 666.73M 689.71M 532.63M 370.45M 251.00M 288.61M
Assets 1.11B 1.12B 649.32M 387.97M 381.35M 298.27M
Liabilities, Current 58.81M 46.07M 27.10M 31.72M 45.16M 38.64M
Liabilities 86.39M 64.94M 28.23M 38.51M 79.83M 100.00M
Stockholders' Equity Attributable to Parent 1.02B 1.06B 621.09M 349.45M 301.51M 198.27M
Common Stock, Shares, Outstanding 87.80M 86.50M 65.04M 48.19M 38.53M 29.54M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -71.10M -247.58M -115.22M -87.17M -55.78M 55.46M
Payments to Acquire Property, Plant, and Equipment 2.37M 3.86M 2.37M 3.44M 2.64M 493.00K
Net Cash Provided by (Used in) Investing Activities 69.98M -502.56M -158.46M -33.40M -69.67M -146.24M
Net Cash Provided by (Used in) Financing Activities 29.78M 677.55M 362.72M 97.17M 145.45M 128.75M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (IDYA CIK 0001676725), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

ASTH

Astrana Health, Inc.

HDSN

HUDSON TECHNOLOGIES INC /NY

RDDT

Reddit, Inc.